Valuation: Profound Medical Corp.

Market Cap 287M 204M 183M 169M 153M 19.39B 290M 2.03B 806M 10.17B 766M 750M 32.24B P/E 2026 *
-6.65x
P/E 2027 * -9.48x
Enterprise Value 287M 204M 183M 169M 153M 19.39B 290M 2.03B 806M 10.17B 766M 750M 32.24B EV / Sales 2026 *
7.68x
EV / Sales 2027 * 4.78x
Free-Float
95.91%
Yield 2026 *
-
Yield 2027 * -
1 day+0.38%
1 week-5.40%
Current month-5.52%
1 month-6.30%
3 months-24.52%
6 months-14.99%
Current year-26.83%
1 week 7.7
Extreme 7.7
8.33
1 month 7.7
Extreme 7.7
10.35
Current year 6.52
Extreme 6.52
12.4
1 year 6.52
Extreme 6.52
12.4
3 years 5.23
Extreme 5.23
16
5 years 4.21
Extreme 4.21
20.44
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 15/08/2016
President 59 01/09/2026
Director of Finance/CFO - 14/08/2026
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 14/06/2018
Director/Board Member 79 14/06/2018
Date Insider Type Main position Quantity % Market Cap. Importance
17/09/26 Option

Chief Technology Officer

25,000 0.0684%
17/09/26 Option

Chief Executive Officer

100,000 0.2737%
17/09/26 Option

Chief Executive Officer

200,000 0.5475%
Change 5-day change 1-year change 3-year change Capi.($)
+0.38%-5.40%+1.55%-29.89% 205M
+1.19%+2.01%+21.05%+57.45% 253B
-0.42%+3.37%+4.03%+19.79% 164B
-1.27%+2.93%-18.41%+71.82% 157B
-1.14%+0.02%-55.43%-9.48% 66.06B
-1.48%-1.05%+6.98%+64.86% 51.52B
-0.99%+2.05%-15.47%-9.20% 52.64B
+0.29%+4.13%+19.34%+44.66% 52.2B
+0.87%+4.47%+19.90%+70.16% 49.61B
+2.76%+7.89%+30.33%+91.68% 44.8B
Average +0.14%+2.11%+1.39%+37.18% 89.07B
Weighted average by Cap. +0.26%+2.65%+2.64%+46.23%

Financials

2026 *2027 *
Net sales 37.36M 26.6M 23.88M 22.05M 19.99M 2.53B 37.82M 264M 105M 1.32B 99.86M 97.72M 4.2B 60.04M 42.75M 38.36M 35.42M 32.12M 4.06B 60.78M 425M 169M 2.13B 160M 157M 6.75B
Net income -43.4M -30.9M -27.73M -25.61M -23.22M -2.93B -43.93M -307M -122M -1.54B -116M -114M -4.88B -31.74M -22.6M -20.28M -18.73M -16.98M -2.15B -32.13M -225M -89.16M -1.13B -84.82M -83.01M -3.57B
Net Debt - -
Projected Income Statement - Annual - Profound Medical Corp.
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
27/10/26 CA$7.880 +0.38% 6,394
26/10/26 CA$7.850 +0.77% 9,091
23/10/26 CA$7.790 -3.59% 18,855
22/10/26 CA$8.080 +0.62% 28,136
21/10/26 CA$8.030 -3.60% 8,469
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Profound Medical Corp.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.850
Average target price
-

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Profound Medical Corp.